Tags

Type your tag names separated by a space and hit enter

Pentoxifylline--a new drug for the treatment of intermittent claudication.
Indian Heart J. 1989 Mar-Apr; 41(2):127-33.IH

Abstract

Pentoxifylline, a xanthine analogue was evaluated for efficacy, safety and tolerance in the treatment of intermittent claudication in a pilot study. Evaluation was performed in 35 cases. 20 patients were given Pentoxifylline in doses of 1200 mg daily, and 15 patients were given placebo for a period of 8 weeks respectively. Pentoxifylline given in doses of 1200 mg was significantly more effective than the placebo in increasing both the initial and absolute claudication distance (ICD & ACD) in patients with chronic occlusive arterial disease. The subjective parameters, such as paraesthesias, muscular cramps and sensation of heaviness in the legs paralleled the course of walking parameters. These results support the hypothesis that Pentoxifylline in doses of 400 mg TDS reduces blood viscosity by improving red cell flexibility, and thereby enhances blood flow in patients with COAD (Fontaine Stage II or Stage III). Pentoxifylline is thus regarded as a promising drug for circulatory ischaemic disorders, especially in intermittent claudication. It was well tolerated with minimal untoward effects.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

2744799

Citation

Chopra, H K., et al. "Pentoxifylline--a New Drug for the Treatment of Intermittent Claudication." Indian Heart Journal, vol. 41, no. 2, 1989, pp. 127-33.
Chopra HK, Chopra KL, Aggarwal KK, et al. Pentoxifylline--a new drug for the treatment of intermittent claudication. Indian Heart J. 1989;41(2):127-33.
Chopra, H. K., Chopra, K. L., Aggarwal, K. K., & Parashar, S. K. (1989). Pentoxifylline--a new drug for the treatment of intermittent claudication. Indian Heart Journal, 41(2), 127-33.
Chopra HK, et al. Pentoxifylline--a New Drug for the Treatment of Intermittent Claudication. Indian Heart J. 1989 Mar-Apr;41(2):127-33. PubMed PMID: 2744799.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pentoxifylline--a new drug for the treatment of intermittent claudication. AU - Chopra,H K, AU - Chopra,K L, AU - Aggarwal,K K, AU - Parashar,S K, PY - 1989/3/1/pubmed PY - 1989/3/1/medline PY - 1989/3/1/entrez SP - 127 EP - 33 JF - Indian heart journal JO - Indian Heart J VL - 41 IS - 2 N2 - Pentoxifylline, a xanthine analogue was evaluated for efficacy, safety and tolerance in the treatment of intermittent claudication in a pilot study. Evaluation was performed in 35 cases. 20 patients were given Pentoxifylline in doses of 1200 mg daily, and 15 patients were given placebo for a period of 8 weeks respectively. Pentoxifylline given in doses of 1200 mg was significantly more effective than the placebo in increasing both the initial and absolute claudication distance (ICD & ACD) in patients with chronic occlusive arterial disease. The subjective parameters, such as paraesthesias, muscular cramps and sensation of heaviness in the legs paralleled the course of walking parameters. These results support the hypothesis that Pentoxifylline in doses of 400 mg TDS reduces blood viscosity by improving red cell flexibility, and thereby enhances blood flow in patients with COAD (Fontaine Stage II or Stage III). Pentoxifylline is thus regarded as a promising drug for circulatory ischaemic disorders, especially in intermittent claudication. It was well tolerated with minimal untoward effects. SN - 0019-4832 UR - https://www.unboundmedicine.com/medline/citation/2744799/Pentoxifylline__a_new_drug_for_the_treatment_of_intermittent_claudication_ DB - PRIME DP - Unbound Medicine ER -